Open AccessPhase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients
Author(s) -
David M. King,
Mark R. Albertini,
Heidi Schalch,
Jacquelyn A. Hank,
Jacek Gan,
Jean Surfus,
David Mahvi,
Joan H. Schiller,
Thomas F. Warner,
KyungMann Kim,
Jens C. Eickhoff,
Kari Kendra,
Ralph A. Reisfeld,
Stephen D. Gillies,
Paul M. Sondel
Publication year - 2004
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2004.11.035
Subject(s) - medicine , melanoma , clinical trial , oncology , cancer research
To evaluate the safety, toxicity, in vivo immunologic activation, and maximum-tolerated dose (MTD) of EMD 273063 (hu14.18-IL-2) in patients with metastatic melanoma.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom